Volasertib (Synonyms: BI 6727)

Name: Volasertib
Brand: MedChemExpress
SKU: HY-12137
Rating: 5.0 (35 reviews)

Cat. No.: HY-12137 Purity: 99.97%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 755038-65-4

사이즈	재고	수량

무료 샘플 (0.1 - 0.2 mg)	지금 신청하기
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	해외재고보유	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	해외재고보유	Estimated Time of Arrival: December 31
Solid
5 mg	해외재고보유	Estimated Time of Arrival: December 31
10 mg	해외재고보유	Estimated Time of Arrival: December 31
25 mg	해외재고보유	Estimated Time of Arrival: December 31
50 mg	해외재고보유	Estimated Time of Arrival: December 31
100 mg	해외재고보유	Estimated Time of Arrival: December 31
200 mg	견적 받기
500 mg	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 35 publication(s) in Google Scholar

Other Forms of Volasertib:

Volasertib trihydrochloride In-stock
Volasertib (Standard) 견적 받기

35 Publications Citing Use of MCE Volasertib

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

: Volasertib purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2025 Nov 21;9(1):373. [Abstract]; MCL17-PDX mice were treated as indicated: vehicle (n = 5), abemaciclib (50 mg/kg, oral, daily; n = 5), and volasertib (5 mg/kg, intraperitoneal, weekly; n = 5). Tumor size was measured every 7 days during the treatment. Tumor volume = length x width2/2. Mice were euthanized after 21 days of treatment. Tumors were excised and weighed in comparison between each group.

: Volasertib purchased from MedChemExpress. Usage Cited in: Sci Signal. 2025 Mar 18;18(878):eadi5174. [Abstract]; BI6727 (BI) treatment rescued the protein levels of PDCD4 resulting from nocodazole (Noc)–mediated mitotic arrest. DU145 shCtl and shPLK1 cells were generated with lentivirus expressing control shRNA or one of two specific PLK1 shRNA, followed by nocodazole (100 ng/ml) or 10 nM BI6727 treatment for 16 hours. The protein levels of PLK1 and PDCD4 were determined by immunoblotting, with β-actin and p-H3 as controls for loading and mitotic arrest. Blots are representative of three independent experiments

: Volasertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Mar 16;15(1):2377. [Abstract]; Immunoblot of NUDT1 p-S121 in Kelly cells treated with PLK1 shRNA or BI6727 (20 nM, 0, 24, 48 h).

: Volasertib purchased from MedChemExpress. Usage Cited in: Cell Discov. 2022 Sep 14;8(1):92. [Abstract]; Cell survival curve for HUTU-80 cells treated with the indicated inhibitors with Volasertib from 0 to 100 μM (36 h).

: Volasertib purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;43(4):1472-1486. [Abstract]; The addition of Volasertib (0.5-1.5 µg/mL blunts the increase of the percentage of annexin-V-binding erythrocytes following glucose deprivation, an effect reaching statistical significance at 1 and 1.5 µg/mL Volasertib.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Polo-like Kinase (PLK) Isoform Specific Products:

View All Isoforms

PLK1 PLK2 PLK3 PLK4

Biological Activity
순도&문서
References
고객리뷰

제품 설명

IC₅₀ & Target^[3]

PLK1

0.87 nM (IC₅₀)

PLK2

5 nM (IC₅₀)

PLK3

56 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	4137 1 Compound: 3; BI 6727	Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
A549	IC₅₀	0.08 3 Compound: BI6727; I	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
A-375	IC₅₀	4137 1 Compound: 3; BI 6727	Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HEK-293T	IC₅₀	1.1 1 Compound: Volasertib	Inhibition of cell growth in HEK293T cells incubated for 72 hrs by CellTiter-blue reagent based assay Inhibition of cell growth in HEK293T cells incubated for 72 hrs by CellTiter-blue reagent based assay	[PMID: 34710325]
A-427	IC₅₀	91 1 Compound: 44	Antiproliferative activity against human A-427 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay Antiproliferative activity against human A-427 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay	[PMID: 37197456]
A-427	IC₅₀	91 1 Compound: 44	Antiproliferative activity against human A-427 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay Antiproliferative activity against human A-427 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay	[PMID: 37197456]
A549	IC₅₀	0.08 3 Compound: BI6727; I	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
MM1.S	IC₅₀	4.5 1 Compound: Volasertib	Inhibition of cell growth in human MM1.S cells incubated for 72 hrs by CellTiter-blue reagent based assay Inhibition of cell growth in human MM1.S cells incubated for 72 hrs by CellTiter-blue reagent based assay	[PMID: 34710325]
A549	IC₅₀	0.08 3 Compound: BI6727; I	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
HCT-116	IC₅₀	0.11 3 Compound: BI6727; I	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
A549	IC₅₀	206.4 1 Compound: 3; BI 6727	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
A549	IC₅₀	206.4 1 Compound: 3; BI 6727	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
DU-145	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
NCI-H23	IC₅₀	53 1 Compound: 44	Antiproliferative activity against human NCI-H23 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay Antiproliferative activity against human NCI-H23 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay	[PMID: 37197456]
HCT-116	IC₅₀	0.11 3 Compound: BI6727; I	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
MCF7	IC₅₀	0.09 3 Compound: BI6727; I	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
DU-145	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
SMMC-7721	IC₅₀	77.2 1 Compound: 3; BI 6727	Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HCT-116	IC₅₀	602.4 1 Compound: 3; BI 6727	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
Granta-519	EC₅₀	15 1 Compound: Chemicel probe : BI 6727	Antimitotic activity against human Granta-519 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human Granta-519 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]
HEK-293T	IC₅₀	1.1 1 Compound: Volasertib	Inhibition of cell growth in HEK293T cells incubated for 72 hrs by CellTiter-blue reagent based assay Inhibition of cell growth in HEK293T cells incubated for 72 hrs by CellTiter-blue reagent based assay	[PMID: 34710325]
HCT-116	EC₅₀	23 1 Compound: Chemicel probe : BI 6727	Antimitotic activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]
MDA-MB-231	IC₅₀	0.11 3 Compound: BI6727; I	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
A-427	IC₅₀	91 1 Compound: 44	Antiproliferative activity against human A-427 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay Antiproliferative activity against human A-427 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay	[PMID: 37197456]
HepG2	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HCT-116	IC₅₀	0.11 3 Compound: BI6727; I	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
HT-29	IC₅₀	1133 1 Compound: 3; BI 6727	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
A549	IC₅₀	206.4 1 Compound: 3; BI 6727	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HCT-116	IC₅₀	602.4 1 Compound: 3; BI 6727	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
PC-3	IC₅₀	0.09 3 Compound: BI6727; I	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
JeKo-1	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
K562	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HCT-116	IC₅₀	602.4 1 Compound: 3; BI 6727	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
KARPAS-299	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HT-29	IC₅₀	1133 1 Compound: 3; BI 6727	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
L02	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
MDA-MB-231	IC₅₀	1482 1 Compound: 3; BI 6727	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
MCF7	IC₅₀	0.09 3 Compound: BI6727; I	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
A-375	IC₅₀	4137 1 Compound: 3; BI 6727	Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
MDA-MB-231	IC₅₀	0.11 3 Compound: BI6727; I	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
DU-145	IC₅₀	<4 1 Compound: 3; BI 6727	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HepG2	IC₅₀	<4 1 Compound: 3; BI 6727	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
MDA-MB-231	IC₅₀	1482 1 Compound: 3; BI 6727	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
MM1.S	IC₅₀	4.5 1 Compound: Volasertib	Inhibition of cell growth in human MM1.S cells incubated for 72 hrs by CellTiter-blue reagent based assay Inhibition of cell growth in human MM1.S cells incubated for 72 hrs by CellTiter-blue reagent based assay	[PMID: 34710325]
JeKo-1	IC₅₀	<4 1 Compound: 3; BI 6727	Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
K562	IC₅₀	<4 1 Compound: 3; BI 6727	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
NCI-H23	IC₅₀	53 1 Compound: 44	Antiproliferative activity against human NCI-H23 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay Antiproliferative activity against human NCI-H23 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay	[PMID: 37197456]
HEK-293T	IC₅₀	1.1 1 Compound: Volasertib	Inhibition of cell growth in HEK293T cells incubated for 72 hrs by CellTiter-blue reagent based assay Inhibition of cell growth in HEK293T cells incubated for 72 hrs by CellTiter-blue reagent based assay	[PMID: 34710325]
PC-3	IC₅₀	0.09 3 Compound: BI6727; I	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
KARPAS-299	IC₅₀	<4 1 Compound: 3; BI 6727	Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HL-60	EC₅₀	32 1 Compound: Chemicel probe : BI 6727	Antimitotic activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]
SMMC-7721	IC₅₀	77.2 1 Compound: 3; BI 6727	Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
L02	IC₅₀	<4 1 Compound: 3; BI 6727	Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HT-29	IC₅₀	1133 1 Compound: 3; BI 6727	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
HepG2	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
JeKo-1	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
K562	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
KARPAS-299	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
L02	IC₅₀	< 4 1 Compound: 3; BI 6727	Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
MCF7	IC₅₀	0.09 3 Compound: BI6727; I	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
MDA-MB-231	IC₅₀	0.11 3 Compound: BI6727; I	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
MDA-MB-231	IC₅₀	1482 1 Compound: 3; BI 6727	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
MM1.S	IC₅₀	4.5 1 Compound: Volasertib	Inhibition of cell growth in human MM1.S cells incubated for 72 hrs by CellTiter-blue reagent based assay Inhibition of cell growth in human MM1.S cells incubated for 72 hrs by CellTiter-blue reagent based assay	[PMID: 34710325]
NCI-H23	IC₅₀	53 1 Compound: 44	Antiproliferative activity against human NCI-H23 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay Antiproliferative activity against human NCI-H23 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay	[PMID: 37197456]
NCI-H460	EC₅₀	21 1 Compound: Chemicel probe : BI 6727	Antimitotic activity against human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]
PC-3	IC₅₀	0.09 3 Compound: BI6727; I	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30572179]
Raji	EC₅₀	11 1 Compound: Chemicel probe : BI 6727	Antimitotic activity against human Raji cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human Raji cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]
SMMC-7721	IC₅₀	77.2 1 Compound: 3; BI 6727	Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay	[PMID: 32814244]
THP-1	EC₅₀	36 1 Compound: Chemicel probe : BI 6727	Antimitotic activity against human THP-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis Antimitotic activity against human THP-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Alamar blue based fluorescence spectrophotometric analysis	[PMID: 19383823]

In Vitro

Volasertib (BI 6727; 0.01-10000 nM; 72 hours) has EC₅₀ values of 11 to 37 nmol/L in multiple cell lines^[1].
Volasertib (10-1000 nM; 24 hours) results accumulation of cells with 4N DNA content, indicative of a cell cycle block in G2-M phase^[1].
Volasertib (100 nM; 24-72 hours) induces cell apoptosis at 48 hours^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	Multiple cell lines
Concentration:	0.01-10000 nM
Incubation Time:	72 hours
Result:	Inhibited proliferation of multiple cell lines derived from various cancer tissues, including carcinomas of the colon (HCT 116, EC₅₀=23 nmol/L) and lung (NCI-H460, EC₅₀=21 nmol/L), melanoma (BRO, EC₅₀=11 nmol/L), and hematopoietic cancers (GRANTA-519, EC₅₀=15 nmol/L; HL-60, EC₅₀=32 nmol/L; THP-1, E₅₀=36 nmol/L and Raji, EC₅₀=37 nmol/L) with EC₅₀ values of 11 to 37 nmol/L.

Apoptosis Analysis^[1]

Cell Line:	NCI-H460 cells
Concentration:	100 nM
Incubation Time:	24, 48, 72 hours
Result:	G2-M arrest at 24 hours was followed by induction of apoptosis at 48 hours.

Cell Cycle Analysis^[1]

Cell Line:	NCI-H460 cells
Concentration:	10, 30, 100, 300, 1000 nM
Incubation Time:	24 hours
Result:	Resulted in accumulation of cells with 4N DNA content, indicative of a cell cycle block in G2-M phase.

In Vivo

Volasertib (BI 6727; A total weekly dose of 50 mg/kg; Oral; once a week, twice a week, or daily; for 40 days) shows comparable efficacy in human colon carcinoma xenograft models^[1].
Volasertib (15, 20, or 25 mg/kg/day; i.v.; 2 consecutive days per week; for 40 days) leads to significant tumor growth delay and even tumor regression in human colon carcinoma xenograft models ^[1].
Volasertib (70 mg/kg given once weekly or 10 mg/kg daily; oral) significantly delays tumor growth in a non-small cell lung carcinoma xenograft model derived from NCI-H460 cells^[1].
Volasertib (a single dose of 40 mg/kg; iv) causes a significant (13-fold) increase in mitotic cells in HCT 116 tumor-bearing nude mice^[1].
Volasertib has high volume of distribution and a long terminal half-life in mice (V_ss=7.6 L/kg, t_1/2=46 h) and rats (V_ss=22 L/kg, t_1/2=54 h)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BomTac:NMRI-Foxn1^nu mice (Taconic) were grafted s.c. with HCT 116 human colon carcinoma cells (ATCC CCL-247)^[1]
Dosage:	A total weekly dose of 50 mg/kg
Administration:	Oral; once a week, twice a week, or daily; for 40 days
Result:	Showed comparable efficacy and were well tolerated.

Animal Model:	Female BomTac:NMRI-Foxn1^nu mice and male Wistar rats of the strain Crl:WI^[1]
Dosage:	35 mg/kg (mice) or 10 mg/kg (rat) (Pharmacokinetic Analysis)
Administration:	IV 5-minute infusion; a single dose 5-minute infusion
Result:	Had high volume of distribution and a long terminal half-life in mice (V_ss=7.6 L/kg, t_1/2=46 h) and rats (V_ss=22 L/kg, t_1/2=54 h).

Clinical Trial

분자량

618.81

화학식

C₃₄H₅₀N₈O₃

CAS No.

755038-65-4

Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C(C1=CC=C(C(OC)=C1)NC2=NC=C(N(C3=O)C)C(N([C@@H]3CC)C(C)C)=N2)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6

선적

Room temperature in continental US; may vary elsewhere.

보관

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

용액&용해도

In Vitro:

DMSO : 23.33 mg/mL (37.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6160 mL	8.0800 mL	16.1600 mL
5 mM	0.3232 mL	1.6160 mL	3.2320 mL
10 mM	0.1616 mL	0.8080 mL	1.6160 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기
농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.36 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

순도&문서

Purity: 99.97%

Select Batch:

Data Sheet (277 KB) SDS (392 KB)

COA (245 KB) HNMR (293 KB) RP-HPLC (233 KB) LCMS (103 KB)

Handling Instructions (2659 KB)

References

[1]. Xie FF, et al. Volasertib suppresses tumor growth in cervical cancer. Am J Cancer Res. 2015 Nov 15;5(12):3548-59. [Content Brief]

[2]. Rudolph D, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.Clin Cancer Res. 2009 May 1;15(9):3094-102. Epub [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6160 mL	8.0800 mL	16.1600 mL	40.4001 mL
	5 mM	0.3232 mL	1.6160 mL	3.2320 mL	8.0800 mL
	10 mM	0.1616 mL	0.8080 mL	1.6160 mL	4.0400 mL
	15 mM	0.1077 mL	0.5387 mL	1.0773 mL	2.6933 mL
	20 mM	0.0808 mL	0.4040 mL	0.8080 mL	2.0200 mL
	25 mM	0.0646 mL	0.3232 mL	0.6464 mL	1.6160 mL
	30 mM	0.0539 mL	0.2693 mL	0.5387 mL	1.3467 mL

Volasertib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
상품명			Requested Quantity *
고객명 *			호칭
메일주소 *			전화번호 *
Department			회사명 *
City			도
Country or Region *
비고

상품명			Lot #
고객명 *			메일주소 *
전화번호			Department *
회사명 *			Country or Region *
비고

Volasertib (Synonyms: BI 6727)

고객리뷰

Other Forms of Volasertib:

35 Publications Citing Use of MCE Volasertib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Polo-like Kinase (PLK) Isoform Specific Products:

Biological Activity

순도&문서

References

고객리뷰

몰농도 계산기

농도 희석 계산기

Complete Stock Solution Preparation Table

Volasertib Related Classifications

Keywords:

최근 본 상품:

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

Volasertib (Synonyms: BI 6727)

고객리뷰

Other Forms of Volasertib:

Volasertib Related Antibodies

35 Publications Citing Use of MCE Volasertib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Polo-like Kinase (PLK) Isoform Specific Products:

Biological Activity

순도&문서

References

고객리뷰

Volasertib Related Antibodies

몰농도 계산기

농도 희석 계산기

Complete Stock Solution Preparation Table

Volasertib Related Classifications

Keywords:

최근 본 상품:

고객리뷰

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report